Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide daily versus weekly formulation PK crossover trial in MC4R pathway genetic obesity
2021-004597-65Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of setmelanotide in Melanocortin-4 receptor pathway disorder (MC4RPD), leptin receptor deficiency, Bardet–Biedl syndrome (BBS) and 1 more (2 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Steady-state pharmacokinetic comparison between once-daily and once-weekly setmelanotide. Started Mar 2022; status: completed.
02
Drugs
setmelanotide
03
Conditions
Melanocortin-4 receptor pathway disorder (MC4RPD)leptin receptor deficiencyBardet–Biedl syndrome (BBS)PCSK1 deficiency (PCSK1D)
Beyond the preview
Go deeper on 2021-004597-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004597-65.